采用GastroPlus 软件发表部分参考文献汇总列表(2022年)
采用GastroPlus 软件发表的部分参考文献汇总列表
(2022年)
导读 01 中国用户发表的部分文章 新型冠状病毒(SARS-CoV-2)蛋白酶抑制FB2001的体外和体内评价 In vitro and in vivo evaluation of the main protease inhibitor FB2001 against SARS-CoV-2. Shang W, Dai W, Yao C, Xu L, Tao X, Li J, Xie X, Xu Y, Su H, Hu M, Xie D, Jiang H, Zhang L, Liu H. Antiviral Res. Volume 208, December 2022. IF=10.103 用于考察丹酚酸 A 的安全性和药代动力学的首次人体研究,并使用PBPK模型模拟该药物的PK First-in-human study to investigate the safety and pharmacokinetics of salvianolic acid A and pharmacokinetic simulation using a physiologically based pharmacokinetic model Jinliang Chen, Zourong Ruan, Honggang Lou, Dandan Yang, Rong Shao, Yichao Xu, Xinhua Hu and Bo Jiang. Front. Pharmacol., 04 November 2022. IF=5.6 一种新型PARP1/2抑制剂Mefuparib (CVL218)的吸收、分布、代谢、排泄 Absorption, distribution, metabolism, and excretion of [14C] Mefuparib (CVL218), a novel PARP1/2 inhibitor, in rats. Li XM, Zheng YD, Zhang YF, Huan XJ, Yang C, Liu ML, Shen XK, Yang CH, Diao XX. Cancer Chemotherapy and Pharmacology. volume 90, pages 499–510 (2022). IF=3.288. 基于PBPK 模型预测加格列净在伴有肝硬化或肾损害的Ⅱ型糖尿病患者中的药动学特征 Prediction of janagliflozin pharmacokinetics in type 2 diabetes mellitus patients with liver cirrhosis or renal impairment using a physiologically based pharmacokinetic model. Hengli Zhao, Yilin Wei, Kun He, Xiaoyu Zhao, HongliMu, Qing Wen. Eur J Pharm Sci. Volume 179, 1 December 2022. IF=5.112. 通过PBPK建模与模拟,预测抗埃博拉病毒的新型双特异性抗体MBS77E的人体PK Translational pharmacokinetics of a novel bispecific antibody against Ebola virus (MBS77E) from animal to human by PBPK modeling & simulation. Wenpeng Zhang, Yanan Xiang , Lingchao Wang , Furun Wang , Guanglu Li, Xiaomei Zhuang. International Journal of Pharmaceutics. 2022 Oct. IF=6.51 开展肾功能不全的儿科患者的PBPK建模,从而优化达托霉素的给药剂量 Physiologically based pharmacokinetic modeling of daptomycin dose optimization in pediatric patients with renal impairment Lingling Ye, Xiang You, Jie Zhou, Chaohui Wu, Meng Ke, Wanhong Wu, Pinfang Huang, Cuihong Lin. Front. Pharmacol. 16 August 2022. IF=5.6 采用生理药代动力学PBPK模型模拟健康受试者和肾功能受损患者的非布司他药代动力学 Simulation of febuxostat pharmacokinetics in healthy subjects and patients with impaired kidney function using physiologically based pharmacokinetic modeling. Xu Y, Chen J, Ruan Z, Jiang B, Yang D, Hu Y, Lou H. (2022). Biopharm Drug Dispos. Jun 24. IF=1.831 替考拉宁的PBPK建模和在肾损伤儿童患者中的剂量调整 Physiologically Based Pharmacokinetic Modeling and Dose Adjustment of Teicoplanin in Pediatric Patients With Renal Impairment Jianwen Xu, Rongfang Lin, Yong Chen, Xiang You, Pinfang Huang, Cuihong Lin. The Journal of Clinical Pharmacology. Vol 62 No 5 2022. IF=2.86 建立ST-246三元环糊精复合物的PBPK模型,从而实现治疗人重症天花的合理静脉输注给药 A PBPK Model of Ternary Cyclodextrin Complex of ST-246 Was Built to Achieve a Reasonable IV Infusion Regimen for the Treatment of Human Severe Smallpox Zhiwei Zhang, Shuang Fu, Furun Wang, Chunmiao Yang, Lingchao Wang, Meiyan Yang, Wenpeng Zhang, Wu Zhong and Xiaomei Zhuang. Front. Pharmacol., 16 March 2022. IF=5.6 左乙拉西坦3D打印速释片的体外和体内生物等效性研究,并采用生理药代动力学PBPK模型考察中国儿童的个体化给药 In Vitro and In Vivo Bioequivalence Study of 3D-Printed Instant-Dissolving Levetiracetam Tablets and Subsequent Personalized Dosing for Chinese Children Based on Physiological Pharmacokinetic Modeling Li X, Liang E, Hong X, Han X, Li C, Wang Y, Wang Z, Zheng A. Pharmaceutics. 2022, 14(1), 20. IF=6.51 预测CYP3A4抑制介导的药物相互作用DDI: 方法的开发和预测性能的评估 Predicting the Drug–Drug Interaction Mediated by CYP3A4 Inhibition: Method Development and Performance Evaluation Ren HC, Sai Y, Chen T, Zhang C, Tang L, Yang CG. The AAPS Journal. volume 24, Article number: 12 (2022). IF=3.603 通过生理药代动力学 (PBPK) 模型预测健康受试者茚达特罗吸入制剂后的药代动力学参数 Prediction of pharmacokinetic parameters of inhaled indacaterol formulation in healthy volunteers using physiologically-based pharmacokinetic (PBPK) model Tang C, Ou-Yang CX, Chen WJ, Zou C, Huang J, Cui C, Yang S, Guo C, Yang XY, Lin Y, Yang GP. European Journal of Pharmaceutical Sciences. Volume 168, 1 January 2022, 106055. IF=5.112 开发普瑞巴林的PBPK模型,以预测肾损伤儿科患者的药代动力学并调整剂量给药方案 Development of Physiologically Based Pharmacokinetic Model for Pregabalin to Predict the Pharmacokinetics in Pediatric Patients with Renal Impairment and Adjust Dosage Regimens Ke C, Lin C, You X, Chen J, Guo G, Wu W, Ye L, Huang P. Journal of Pharmaceutical Sciences. Volume 111, Issue 2, February 2022, Pages 542-551. IF=3.784 采用头孢羟氨苄的小鼠、大鼠、人体的PBPK模型,预测感染器官组织中的药时曲线 Physiologically Based Pharmacokinetic Modeling of Cefadroxil in Mouse, Rat, and Human to Predict Concentration–Time Profile at Infected Tissue Zhongxia Tan, Youxi Zhang, Chao Wang, Le Sun. Front Pharmacol. 2021; 12: 692741. IF=5.6 Pharmacokinetics and Disposition of Heparin-Binding Growth Factor Midkine Antisense Oligonucleotide Nanoliposomes in Experimental Animal Species and Prediction of Human Pharmacokinetics Using a Physiologically Based Pharmacokinetic Model. Haihong Bai, Yuanguo Cheng, and Jinjing Che. Front Pharmacol. Volume 12 – 2021. IF=5.988 李亚梅,谢潘潘,张瑜,杨明,刘晓慧,史爱欣. 《中国医院药学杂志》2022年12月第42卷第23期. 综合影响因子=1.255 PBPK模型在抗感染药物研发及临床评价中的应用 董柳含,许小菊, 王瑾, 蔡芸.《中国抗生素杂志》2022年10月第47卷第10期. 综合影响因子=1.181 生理药代动力学模型用于中药风险评估的思考及认识 苏布达,李晓萌,刘慧,杨珅珅,魏金霞,李遇伯. 《中草药》 2022 年8 月 第53 卷 第15 期. 综合影响因子=3.18 基于PBPK模型预测不同晶型利福平的生物等效性 蔡其霖,黎文星,严真,尹莉芳.《中国药科大学学报》 2022,53(2):207 - 214. 综合影响因子=0.811 生理药动学模型结合全细胞膜片钳技术评价胺碘酮和去乙基胺碘酮的体外心脏安全性 杜海燕,李静,张颖超,赵桂平,刘之光,郭成军,苏俊武,林阳. 《中国医药》2022年7月第17 卷第7期. 综合影响因子=1.607 胺碘酮和去乙基胺碘酮健康人体复合生理药动学模型建立及组织分布特征预测 杜海燕, 刘文芳,谭莉,仇琪,周子杰,王钰玺,林阳. 《中国医药》2022 年5 月第17 卷第5 期. 综合影响因子=1.607 基于生理药代动力学模型对盐酸莫西沙星有效性的研究 高婕,冯芳,王立新,崇小萌,王晨,尹利辉. 《药学学报》. 2022,57(07). 综合影响因子=1.916 生理药动学模型结合体外溶出试验评价瑞格列奈片的生物等效性 黄丹,甘加明,陈冬华,严全鸿.《中国现代应用药学》. 2022,39(01). 综合影响因子=1.275 基于 PBPK-TO 模型预测CYP3A4 调节剂对卡博替尼PK/PD 的影响 江晓泉,汪国鹏,刘憬曈,潘福璐,森慕黎,杨文宁,刘洋,王中健. 《中国药学杂志》2022,57(16). 综合影响因子=1.098 已公布的卡马西平片参比制剂在体内外的相关性研究 吴斌,张树栋,吴兆伟,于海珍,朱晓月,王琳,胡琴,张喆.《中国药学杂志》.2022,57(11). 综合影响因子=1.098 国产非那雄胺片与原研制剂体外溶出一致性评价及采用计算机模拟技术建立体内外相关性模型研究 曾庆花,邓鸣,杨娜,朱健萍,卢日刚.《中国药学杂志》2022 年7 月第57 卷第13 期.综合影响因子=1.098 以兰索拉唑肠溶胶囊为例探索模型引导的仿制药等效性替代方法 张锦琳,李岩,陈涛,周颖,宋芸峰,贾欢欢,袁耀佐,张玫,曹玲.《药学与临床研究》. 2022,30(01). 综合影响因子=0.643 已公布的卡马西平片参比制剂在体内外的相关性研究 02 其他国家用户发表的部分文章,或涉及的综述等 支持口服药品开发的制剂桥接方法 Approaches of formulation bridging in support of orally administered drug product development Murui Han, Jin Xu, Yiqing Lin. International Journal of Pharmaceutics. Volume 629, 15 December 2022. IF=6.51 使用胃肠模拟器、质量传输分析和吸收模拟来研究pH调节剂在减轻与胃pH相关的弱碱性药物性能问题方面的影响: 以Palbociclib为研究案例 Use of Gastrointestinal Simulator, Mass Transport Analysis, and Absorption Simulation to Investigate the Impact of pH Modifiers in Mitigating Weakly Basic Drugs’ Performance Issues Related to Gastric pH: Palbociclib Case Study. Kuminek G, Waltz NM, Sperry DC, Greenwood DE, Hate SS, Amidon GE. Mol. Pharmaceutics. November 11, 2022. IF=5.364 预测正确的儿童给药剂量:儿科生理药代动力学建模工具的作用 Predicting the correct dose in children: Role of computational Pediatric Physiological-based pharmacokinetics modeling tools. Zhou X, Dun J, Chen X, Xiang B, Dang Y, Cao D. CPT Pharmacometrics Syst Pharmacol. November 2022. IF=4.938 将机制性建模应用到皮肤药品:该研讨会的汇总报告 Mechanistic modeling of drug products applied to the skin: A workshop summary report Tsakalozou E, Alam K, Ghosh P, Spires J, Polak S, Fang L, Sammeta S, Zhao P, Arora S, Raney SG. Pharmacometrics & Systems Pharmacology. 2022, Volume 12, Issue 5 p. 575-584. IF=4.938 盐酸甲氧氯普胺胃滞留膜的制剂处方及用Gastroplus® PBPK软件进行体外-计算机虚拟预测 Formulation of metoclopramide HCl gastroretentive film and in vitro- in silico prediction using Gastroplus® PBPK software. Hamdi DS, Mohamed MBM. Saudi Pharmaceutical Journal. Volume 30, Issue 12, December 2022. IF=4.562 推断白色念珠菌的治疗靶点和相关天然产物可能的抑制作用:亲和力和生理药代动力学方法的简介 Inferring Therapeutic Targets in Candida albicans and Possible Inhibition through Natural Products: A Binding and Physiological Based Pharmacokinetics Snapshot. Basharat Z, Khan K, Jalal K, Alnasser SM, Majeed S, Zehra M. Life. Volume 12 Issue 11. 2022. IF=3.253 通过PBPK建模与模拟,考察大麻素在人体血浆和组织中的PK Physiologically based pharmacokinetic modeling and simulation of cannabinoids in human plasma and tissues. Liu Y, Sprando RL. J Appl Toxicol. October 2022. IF=3.628. 使用临床前种属数据评估不确定度,并采用Rodgers-Lukacova模型矫正人体分布容积的预测 Utility of preclinical species for uncertainty assessment and correction of prediction of human volume of distribution using the Rodgers-Lukacova model. Sherbetijan E, Peters SA, Petersson C. Xenobiotica. October 2022. IF=1.997 用于治疗细菌性败血症的阿米卡星脂质体的体外抗菌活性和静脉给药后的体内PK In vitro antibacterial activity and in vivo pharmacokinetics of intravenously administered Amikacin-loaded Liposomes for the management of bacterial septicaemia. Maxwell A, Chaudhari BB, Chaudhari P, Ananthamurthy K, Aranjani J, Moorkoth S, Ghate V, Lewis S. Colloids and Surfaces B: Biointerfaces. Volume 220, December 2022. IF=5.999 SeDeM工具驱动的全因子设计用于盐酸曲马多的渗透给药:制剂处方开发、理化性质评价、PBPK建模(GastroPlus™)预测PK SeDeM tool-driven full factorial design for osmotic drug delivery of tramadol HCl: Formulation development, physicochemical evaluation, and in-silico PBPK modeling for predictive pharmacokinetic evaluation using GastroPlus™. Saleem MT, Shoaib MH, Yousuf RI, Ahmed FR, Ahmed K, Siddiqui F, Mahmood ZA, Imtiaz MS. Front. Pharmacol. October 2022. IF=5.6 将预测或实测数据整合到PBPK模型中,能否准确预测高脂溶化合物的临床PK?以12个高脂溶性化合物为例. Can We Predict Clinical Pharmacokinetics of Highly Lipophilic Compounds by Integration of Machine Learning or In Vitro Data into Physiologically Based Models? A Feasibility Study Based on 12 Development Compounds. Parrott N, Manevski N, Olivares-Morales A. Molecular Pharmaceutics. 2022, 19(11): 3858-3868. IF=5.364 开发用于预测糖尿病患者药物处置的PBPK模型 Development of physiologically based pharmacokinetics model for prediction of drug disposition in diabetic patients Alqahtani S, Alsaleh H, Alsultan A.Journal of Translational Science. October 29, 2022. IF=2.12 使用PBPK建模和模拟外推眼部给药溶液的临床暴露 Clinical Ocular Exposure Extrapolation for Ophthalmic Solutions Using PBPK Modeling and Simulation. LeMerdy M, AlQaraghuli F, Tan ML, Walenga RL, Babiskin A, Zhao L, Lukacova V. Pharmaceutical Research. (2022). IF=4.580 考察生理药代动力学模型用于无动物评估化妆品成分的预测精度的不确定性 Investigating the uncertainty of prediction accuracy for the application of physiologically based pharmacokinetic models to animal-free risk assessment of cosmetic ingredients. Shimpei Terasak, Akane Hayashi, Yuko Nukada, Masayuki Yamane. Regulatory Toxicology and Pharmacology. Volume 135, November 2022. IF=3.598 儿科研究中的胃肠液体积:回顾性MRI研究 Gastrointestinal Fluid Volumes in Pediatrics: A Retrospective MRI Study. Van der Veken M, Aertsen M, Brouwers J, Stillhart C, Parrott N, Augustijns P. Pharmaceutics. 2022, 14(9). IF=6.525 PBBM模型在监管审评中的应用:替代f2,赋能生物豁免,创建溶出安全空间 Utility of Physiologically Based Biopharmaceutics Modeling (PBBM) in Regulatory Perspective: Application to Supersede f2, Enabling Biowaivers & Creation of Dissolution Safe Space. Adithya Karthik Bhattiprolu, et al. J Pharm Sci. 2022 Sep. IF=3.784 在化学品的风险评估中,基于生理的动力学(PBK)模型的体外-体内外推(IVIVE)的最佳使用和监管认可 Towards best use and regulatory acceptance of generic physiologically based kinetic (PBK) models for in vitro-to-in vivo extrapolation (IVIVE) in chemical risk assessment. Abdulkarim Najjar, et al. Archives of Toxicology. volume 96, pages3407–3419 (2022). IF=6.168 在有吸收时间限制概念的角度下的PBPK模型 Physiologically based Pharmacokinetic Models under the Prism of the Finite Absorption Time Concept. Di Wu, Athanasios A. Tsekouras, Panos Macheras, Filippos Kesisoglou. Pharm Res. 2022 Sep. IF=4.580 用于透皮给药递送的纳米层复合膜:开发、表征以及计算机建模和模拟 Nanoclay-Based Composite Films for Transdermal Drug Delivery: Development, Characterization, and in silico Modeling and Simulation. Sikandar M, Shoaib MH, Yousuf RI, Ahmed FR, Ali FR, Saleem MT, Ahmed K, Sarfaraz S, Jabeen S, Siddiqui F, Husain T, Qazi F, Imtiaz MS. (2022). Int J Nanomedicine. Aug 4; 17:3463-3481. IF= 7.033 珊瑚吡喃菌素A小规模制剂制备的体外-体内关系IVIVR In Vitro-In Vivo Relationship in Mini-Scale-Enabling Formulations of Corallopyronin A. Becker T, Krome AK, Vahdati S, Schiefer A, Pfarr K, Ehrens A, Aden T, Grosse M, Jansen R, Alt S, Hesterkamp T, Stadler M, Hübner MP, Kehraus S, König GM, Hoerauf A, Wagner KG. (2022). Pharmaceutics. Aug 9;14(8):1657. IF= 6.525 氯苯氧基除草剂MCPA:在人体、大鼠、犬中观测到的毒理曲线差异的机理基础 The chlorophenoxy herbicide MCPA: a mechanistic basis for the observed differences in toxicological profile in humans and rats versus dogs. Gledhill A, Bowen R, Bartels M, Bond A, Chung G, Brown C, Pye K, Vora T. (2022) Xenobiotica. Jul 28:1-13. IF=1.997 开发穿心莲内酯的小鼠生理学药代动力学 (PBPK) 模型,并将其放大到大鼠、狗和人体 The Development of a Physiologically Based Pharmacokinetic (PBPK) Model of Andrographolide in Mice and Scaling It up to Rats, Dogs and Humans. Talapphetsakun T, Viyoch J, Waranuch N, Sermsappasuk P. (2022) . Curr Drug Metab. Jun 28. IF=3.408 减肥患者的抗过敏治疗:减肥手术后氯雷他定而非地氯雷他定的溶解度/溶出度和生物利用度降低的可能性 Antiallergic Treatment of Bariatric Patients: Potentially Hampered Solubility/Dissolution and Bioavailability of Loratadine, but Not Desloratadine, Post-Bariatric Surgery. Porat D, Dukhno O, Vainer E, Cvijić S, Dahan A. (2022). Mol. Pharmaceutics. Aug 1;19(8):2922-2936. IF=5.364 体内暴露于毒理响应关系的计算方法进展 Advances in computational methods along the exposure to toxicological response paradigm. El-Masri H, Paul Friedman K, Isaacs K, Wetmore BA. (2022). Toxicology and Applied Pharmacology. Sep 1;450:116141. IF=4.46 使用 Tiny-TIM 溶出度和计算机模拟加速 BCS II 类化合物口服制剂的开发 Using Tiny-TIM Dissolution and In Silico Simulation to Accelerate Oral Product Development of a BCS Class II Compound. Luo L, Thakral NK, Schwabe R, Li L, Chen S. (2022). AAPS PharmSciTech. Jul 1;23(6):185. IF=3.951 跨细胞旁路转运在米诺地尔的肠道吸收和生物药剂学特性中的作用 The Role of Paracellular Transport in the Intestinal Absorption and Biopharmaceutical Characterization of Minoxidil. Markovic M, Zur M, Garsiani S, Porat D, Cvijić S, Amidon GL, Dahan A. (2022). Pharmaceutics. Jun 27;14(7):1360. IF=6.525 具有生物预测力的溶出方法在口服固体剂型开发中的应用:当前的行业经验 Applications of bio-predictive dissolution tools for the development of solid oral dosage forms: current industry experience. Xu J, Zhang L, Shao X. (2022). Drug Development and Industrial Pharmacy. Jul 13:1-19. IF=3.727 用于恢复皮质醇生理昼夜节律的生物钟疗法:基于氢化可的松调释制剂 Chronotherapy based on modified-release hydrocortisone to restore the physiological cortisol diurnal rhythm. Whitaker MJ, Huatan H, Ross RJ. (2022). Drug Deliv Transl Res. May 26. IF=5.671 在 CYP3A 或 P-gp 抑制剂、CYP3A 诱导剂和胃酸减少剂存在的情况下,考察asciminib 的药代动力学 Pharmacokinetics of asciminib in the presence of CYP3A or P-gp inhibitors, CYP3A inducers, and acid-reducing agents. Hoch M, Huth F, Sato M, Sengupta T, Quinlan M, Dodd S, Kapoor S, Hourcade-Potelleret F. (2022) Clin Transl Sci. May 26. IF=4.516 酮康唑的固体脂质纳米颗粒的成份和形态对肠道渗透的影响,和通过GastroPlus 开展预测的研究 Impact of Composition and Morphology of Ketoconazole-Loaded Solid Lipid Nanoparticles on Intestinal Permeation and GastroPlus-Based Prediction Studies. Aljurbui SJ, Hussain A, Yusuf M, Ramzan M, Afzal O, Almohaywi B, Yasmin S, Altamimi ASA. (2022) ACS Omega. 7(26):22406-22420. IF=4.132 通过体外试验比较三氯生和其结构相似的化学品之间的毒性效应和体内暴露水平进行交叉参考法的案例研究 Comparison of toxicological effects and exposure levels between triclosan and its structurally similar chemicals using in vitro tests for read-across case study. Nakagawa S, Hayashi A, Nukada Y, Yamane M. (2022) Regul Toxicol Pharmacol. 132:105181. IF=3.598 开发口服药品的具有临床相关性的溶出标准 (CRDS):虚拟系列网络研讨会 Developing Clinically Relevant Dissolution Specifications (CRDSs) for Oral Drug Products: Virtual Webinar Series. McAllister M, et al. (2022). Pharmaceutics. May 7; 14(5): 1010. IF=6.525 生理药代动力学PBPK分析在生物药剂学中的应用—监管机构和工业界观点 The Use of Physiologically Based Pharmacokinetic Analyses-in Biopharmaceutics Applications -Regulatory and Industry Perspectives. Anand O, Pepin XJH, Kolhatkar V, Seo P. (2022). Pharm Res. May 18. IF=4.580 采用基于生理学的生物药剂学PBBM模型,预测维格列汀调释 (MR) 片剂在体内的性能并建立具有临床相关性的溶出标准 Physiologically Based Biopharmaceutics Model of Vildagliptin Modified Release (MR) Tablets to Predict In Vivo Performance and Establish Clinically Relevant Dissolution Specifications. Madny MA, Deshpande P, Tumuluri V, Borde P, Sangana R. (2022). AAPS PharmSciTech. Apr 6;23(4):108. IF=3.951 通过基于生理学的生物药剂学模型 (PBBM) 模型指导的弱碱性化合物的制剂制备 An Enabling Formulation of a Weakly Basic Compound Guided by Physiologically Based Biopharmaceutics Modeling (PBBM). Ibrahim F. (2022) J Pharm Sci. Apr 16:S0022-3549 (22)00152-6. IF=3.784 通过实验设计DoE和基于生理学的生物药剂学PBBM模型,支持美托洛尔的缓释微型片剂的开发 Development of Extended-Release Mini-Tablets Containing Metoprolol Supported by Design of Experiments and Physiologically Based Biopharmaceutics Modeling. Issa MG, de Souza NV, Jou BWC, Duque MD, Ferraz HG. (2022). Pharmaceutics. 14(5):892. IF=6.525 评估高通量PBPK建模的预测成功率,从而引导早期药物发现 Evaluation of the Success of High-Throughput Physiologically Based Pharmacokinetic (HT-PBPK) Modeling Predictions to Inform Early Drug Discovery. Naga D, Parrott N, Ecker GF, Olivares-Morales A. (2022) Mol Pharm. Apr 27. IF=5.364 使用大鼠的体内和计算机 PBPK 模型,评估环丙沙星溶液肺内给药对呼吸道感染的药代动力学 Evaluating the pharmacokinetics of intrapulmonary administered ciprofloxacin solution for respiratory infections using in vivo and in silico PBPK rat model studies. Shi C, Ignjatović J, Wang J, Guo Y, Zhang L, Cvijić S, Cun D, Mingshi Yang M. (2022). Chinese Chemical Letters. Apr 29. IF=8.455 局部给药的PBK建模和Cmax 估算的不确定性的表征:案例研究方法 PBK modelling of topical application and characterisation of the uncertainty of Cmax estimate: A case study approach. Li H, Reynolds J, Sorrell I, Sheffield D, Pendlington R, Cubberley R, Nicol B. (2022) Toxicology and Applied Pharmacology. May 1;442:115992. IF=4.46 IQ 联盟对于溶出方法与体内性能联系起来的观点:通过工业数据库分析和案例研究拟定工作流程 An IQ Consortium Perspective on Connecting Dissolution Methods to In Vivo Performance: Analysis of an Industrial Database and Case Studies to Propose a Workflow. Aburub A, Chen Y, Chung J, Gao P, Good D, Hansmann S, Hawley M, Heimbach T, Hingle M, Kesisoglou F, Li R, Rose J, Tisaert C. (2022) AAPS J. Mar 29;24(3):49. IF=3.603 通过 GastroPlus 的PBPK建模预测2-苯氧乙醇及其代谢物 2-苯氧乙酸口服和透皮给药后,化合物在大鼠和人体组织器官和尿液中的浓度 Prediction of tissue and urine concentrations of 2-phenoxyethanol and its metabolite 2-phenoxyacetic acid in rat and human after oral and dermal exposures via GastroPlus physiologically based pharmacokinetic modelling. Zhang F, LeBaron MJ, Marty MS. (2022). SAR QSAR Environ Res. Mar 18:1-17. IF=3.681 通过蛋白质组学引导PBPK建模,探索乙胺丁醇诱导眼部毒性的可能机制 Exploration of the Plausible Mechanism of Ethambutol Induced Ocular Toxicity by Using Proteomics Informed Physiologically Based Pharmacokinetic (PBPK) Modeling. Balhara A, Ladumor MK, Nankar RP, Syed SD, Giri S, Prasad B, Singh S. (2022) Pharm Res. Mar 17. IF=4.580 破译 FLT 的免疫病理学作用,评估用于治疗白血病的新型拓扑异构酶和突变型 FLT3 双重抑制剂 Deciphering the immuno-pathological role of FLT, and evaluation of a novel dual inhibitor of topoisomerases and mutant-FLT3 for treating leukemia Lawal B, Kuo YC, Khedkar H, Mokgautsi N, Sumitra MR, Wu AT, Huang HS. Am J Cancer Res. 2022; 12(11): 5140–5159. IF=6.160 预测小分子候选药物人体PK 的当前方法:来自 IQ 人体 PK 预测工作组调查的结果 Current Approaches for Predicting Human PK for Small Molecule Development Candidates: Findings from the IQ Human PK Prediction Working Group Survey Petersson C, et al. The AAPS Journal. volume 24, Article number: 85 (2022). IF=3.603 一种潜在的速效血期抗疟疾药INE963的发现和临床前药理学研究,该化合物具有高耐药性屏障和单剂量治疗无并发症疟疾的潜力 Discovery and Preclinical Pharmacology of INE963, a Potent and Fast-Acting Blood-Stage Antimalarial with a High Barrier to Resistance and Potential for Single-Dose Cures in Uncomplicated Malaria Taft BR, et al. J. Med. Chem. 2022, 65, 5, 3798–3813. IF=8.039 通过计算机预测神经毒性的体内神经生理学:香茅醛、3,4-二氯-1-丁烯和溴乙酸苄酯 In vivo neurophysiological assessment of in silico predictions of neurotoxicity: Citronellal, 3,4-dichloro-1-butene, and benzyl bromoacetate Jung GL, McDaniel KL, LoPachin RM, Geohagen BC, Smith A, Huffstickler M, Herr DW. NeuroToxicology. Volume 90, May 2022, Pages 48-61. IF=4.398 综述:新型盐皮质激素受体拮抗剂依沙酮的临床药代动力学和药效学研究进展 Clinical Pharmacokinetics and Pharmacodynamics of Esaxerenone, a Novel Mineralocorticoid Receptor Antagonist: A Review Janković SM, Jankovic SV. European Journal of Drug Metabolism and Pharmacokinetics. volume 47, pages 291–308 (2022). IF=2.569 用于定量评估核受体肝 X (LXR) 和孕烷 X (PXR) 对化学诱导的肝脂肪变性的作用的一种基于生物学的模型 A biologically based model to quantitatively assess the role of the nuclear receptors liver X (LXR), and pregnane X (PXR) on chemically induced hepatic steatosis Bay C, El-Masri HA. Toxicology Letters. Volume 359, 15 April 2022, Pages 46-54. IF=4.271 开发十氯酮(杀虫、杀真菌药)的生理药代动力学模型,以支持对人体健康风险的评估 Chlordecone: development of a physiologically based pharmacokinetic tool to support human health risks assessments Emond C, Multigner L. Archives of Toxicology. volume 96, pages1009–1019 (2022). IF=6.168 系统性综述:评估建模和模拟的预测能力以确定吸入药物的生物等效性 Assessment of the predictive capability of modelling and simulation to determine bioequivalence of inhaled drugs: A systematic review Rebello J, Brashier B, Shukla S. DARU Journal of Pharmaceutical Sciences. volume 30, pages 229–243 (2022). IF=4.088 在药物发现阶段,剂量数作为指导优化先导化合物优化口服生物利用度的方法 Dose Number as a Tool to Guide Lead Optimization for Orally Bioavailable Compounds in Drug Discovery Wuelfing WP, El Marrouni A, Lipert MP, Daublain P, Converso A, Templeton AC J. Med. Chem. 2022, 65, 3, 1685–1694. IF=8.039 采用计算机预测 MDI 原料药透皮给药或吸入给药后的体内吸收,以支持基于类别的交叉评估 In silico predictions of absorption of MDI substances after dermal or inhalation exposures to support a category based read-across assessment Bartels M, van Osdol W, Le Merdy M, Chappelle A, Kuhl A, West R. Regulatory Toxicology and Pharmacology. Volume 129, March 2022, 105117. IF=3.598 药物颗粒表面pH导致的溶出挑战:整合到机制性口服吸收模型中 Dissolution Challenges Associated with the Surface pH of Drug Particles: Integration into Mechanistic Oral Absorption Modeling Hens B, Seegobin N, Tsume Y, Clear N, McAllister M, Amidon GE, Amidon GL. The AAPS Journal. volume 24, Article number: 17 (2022). IF=3.603 合成醛糖还原酶抑制剂 (SE415)在{PEG 400 (1) + 水 (2)} 共溶剂混合物中优先溶剂化研究和基于 GastroPlus 的预测 Preferential Solvation Study of the Synthesized Aldose Reductase Inhibitor (SE415) in the {PEG 400 (1) + Water (2)} Cosolvent Mixture and GastroPlus-Based Prediction Hussain A, Altamimi MA, Afzal O, Altamimi ASA, Ali A, Ali A, Martinez F, Siddique MUM, Acree WE, Jouyban A. ACS Omega. 2022, 7, 1, 1197–1210. IF=4.132 PBPK/PBBM建模在仿制药开发中的应用:工业界观点 Applications of PBPK/PBBM modeling in generic product development: An industry perspective Yuvaneshwari K, Sivacharan Kollipara, Tausif Ahmed, Siddharth Chachad. Journal of Drug Delivery Science and Technology. Volume 69, March 2022, 103152. IF=5.062 当前模拟药物在胃肠道中渗透性模型的最佳实践——UNGAP 综述 Best practices in current models mimicking drug permeability in the gastrointestinal tract – an UNGAP review O’Shea JP, Augustijns P, Brandl M, Brayden DJ, Brouwers J, Griffin BT, Holm R, Jacobsen AC, Lennernäs H, Vinarov Z, O’Driscoll CM. European Journal of Pharmaceutical Sciences. Volume 170, 1 March 2022, 106098. IF=5.112 用于眼部给药的酮康唑超分子热敏凝胶:计算机预测、体外和离体研究 A supramolecular thermosensitive gel of ketoconazole for ocular applications: In silico, in vitro, and ex vivo studies Chaudhari P, Naik R, Sruthi Mallela L, Roy S, Birangal S, Ghate V, Balladka Kunhanna S, Lewis SA. International Journal of Pharmaceutics. Volume 613, 5 February 2022, 121409. IF=6.50 开发用于治疗发作性睡病和特发性嗜睡症患者的低钠羟丁酸钠制剂 Development of a lower-sodium oxybate formulation for the treatment of patients with narcolepsy and idiopathic hypersomnia Junnarkar G, Allphin C, Profant J, Steininger TL, Chen C, Zomorodi K, Skowronski R, Black J. Expert Opinion on Drug Discovery. Volume 17, 2022 - Issue 2. IF=7.050 通过基于生理学的生物药剂学PBBM模型预测多种来源的阿昔洛韦口服药品的药代动力学 Predicting pharmacokinetics of multisource acyclovir oral products through physiologically based biopharmaceutics modeling García MA, Bolger MB, Suarez-Sharp S, Langguth P. Journal of Pharmaceutical Sciences. Volume 111, Issue 1, January 2022, Pages 262-273. IF=3.784 通过生理学的生物药剂学PBBM模型展示Ribociclib 的虚拟生物等效性和生物等效性的安全空间,该药物的吸收为渗透限速 Physiologically Based Biopharmaceutics Modeling to Demonstrate Virtual Bioequivalence and Bioequivalence Safe-Space for Ribociclib which has Permeation Rate-Controlled Absorption Laisney M, Heimbach T, Mueller-Zsigmondy M, Blumenstein L, Costa R, Ji Y. Journal of Pharmaceutical Sciences. Volume 111, Issue 1, January 2022, Pages 274-284. IF=3.784 深共晶液体作为利培酮透皮给药的载体 Deep eutectic liquid as transdermal delivery vehicle of Risperidone Daadoue S, Al-Remawi M, Al-Mawla L, Idkaidek N, Khalid RM, Al-Akayleh F. Journal of Molecular Liquids. Volume 345, 1 January 2022, 117347. IF=6.633 Nemiralisib吸入制剂的PBPK模型:肺部吸收组分、体循环分布和口服吸收的机理 Physiologically Based Pharmacokinetic Modelling of Inhaled Nemiralisib: Mechanistic Components for Pulmonary Absorption, Systemic Distribution, and Oral Absorption Miller NA, Graves RH, Edwards CD, Amour A, Taylor E, Robb O, O’ Brien B, Patel A, Harrell AW, Hessel EM. Clinical Pharmacokinetics. volume 61, pages281–293 (2022). IF=5.577 鉴定 COVID-19 感染的新型免疫炎症特征,评估新型喹诺酮小分子衍生物 RXn-02 的药代动力学和治疗潜力 Identification of a novel immune-inflammatory signature of COVID-19 infections, and evaluation of pharmacokinetics and therapeutic potential of RXn-02, a novel small-molecule derivative of quinolone Lawal B, Kuo YC, Rachmawati Sumitra M, Wu ATH, Huang HS. Computers in Biology and Medicine. Volume 148, September 2022, 105814. IF=7.7 PDF 版文献汇总列表下载 https://www.jianguoyun.com/p/Dcap4M8Q_a64BxirjJMFIAA (复制到浏览器)